Allergopharma GmbH & Co. KG would like to inform you about the latest recommendations from German specialist societies and allergy experts regarding the corona pandemic for patients with allergic diseases. Regarding the current highly dynamic situation, we have summarized new insights for you in our third update.
We obtain our information from the current position papers published by the specialist societies Allergic Rhinitis and its Impact on Asthma (ARIA), European Academy of Allergy and Clinical Immunology (EAACI), Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and the Society for Pediatric Allergology and Environmental Medicine (GPA)
A change in allergen immunotherapy is not required. The Society for Pediatric Allergology and Environmental Medicine (GPA) has commented in detail (https://www.gpau.de/index.php?id=573):
Switching from subcutaneous to sublingual treatment is not reasonable and necessary, as there is no increased risk from SCIT when used in accordance with the indication, and the uncertainty of the patient and necessary contacts for detailed advice on the change in therapy and for the administration of the first dose under medical supervision are not expedient.
In order to avoid unnecessary contacts, patients should preferably contact the doctor by phone before starting or restarting AIT, and their symptoms and contraindications should be used to assess whether an AIT is beneficial.
Since a moderate to severe COVID-19 infection course might affect various organs, it should also be checked before starting / restarting the AIT, whether special laboratory tests such as blood count, liver / kidney function test or lung function test are necessary, since it has to be ensured that the patient is fully recovered.
This question is answered in detail in this position paper of the specialist societies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323448/pdf/ALL-9999-na.pdf
National and international specialist societies recommend continuing the individual therapy for asthma. This also includes the therapy with inhaled corticosteroids.
Changing or interrupting asthma therapy without consulting a doctor could result in worsening of the symptoms and thus unnecessary visits to the doctor and hospitalization. This increases the risk of coming into contact with a person suffering from COVID-19 and thereby becoming infected.
A detailed statement of the experts regarding this issue can also be found in this position paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362395/
So far, there is little data on prognoses and symptoms of COVID-19 disease in children, but it is currently estimated that children account for only 1-5% of infected COVID-19 patients. At the current state of knowledge, children suffering from COVID-19 have less difficulty breathing, less cough and less fever, and become less often eriously ill compared to adult patients. In addition, the mortality rate in children is extremely low.
Presently available data do not indicate that children with a controlled allergic disease are at an increased risk of developing COVID-19 compared to children without allergic diseases. In general, it can be assumed that children can transmit the virus despite the generally mild course of disease progression.
A detailed statement of the experts regarding this issue can also be found in this position paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264548/
The personal designations used here should be construed as applying to male, female and diverse persons.